FDA Approves Nivolumab Plus Ipilimumab for Malignant Pleural Mesothelioma
October 3rd 2020The FDA approved nivolumab (Opdivo) plus ipilimumab (Yervoy) for the frontline treatment of adults with unresectable, malignant, pleural mesothelioma (MPM), according to Bristol Myers Squibb, the manufacturer of the immunotherapy agents.
FDA Approves Pralsetinib for RET Fusion Positive Metastatic NSCLC
September 5th 2020The Food and Drug Administration (FDA) approved pralsetinib (Gavreto) for the treatment of patients with metastatic, RET fusion-positive non-small cell lung cancer (NSCLC), according to Genentech, the co-manufacturer of the drug.